title: Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
abstract: BACKGROUND
  To analyse the 24-month outcomes of intravitreal ranibizumab injections for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).
  
  
  METHODS
  The authors reviewed the charts of all consecutive eyes with CNV secondary to AMD, who underwent one intravitreal ranibizumab injection (followed by a pro re nata (1+PRN) decision to retreat or to not retreat) at least 24 months before. Best-corrected visual acuity (BCVA) changes and central macular thickness (CMT) were retrospectively assessed, from baseline (m0) to month 12 (m12), and 24 (m24).
  
  
  RESULTS
  Ninety-six eyes of 79 patients (23 male, 56 female, aged 63-90 years) were included for analysis. The number of intravitreal injections administered ranged from 1 to 16. The mean BCVA significantly improved from m0 (0.78+/-0.33) to m12 (0.61+/-0.39, p<0.001), and m24 (0.65+/-0.38, p<0.001). The mean CMT significantly decreased from m0 (323.7+/-118.1) to m12 (254.6+/-92.3, p<0.001), and m24 (259.0+/-89.9, p<0.001). At m24, subretinal fluid, cystoid macular oedema and pigment epithelium detachment were present in fewer eyes (13, 31 and 31 eyes respectively), compared with m0 (33, 61 and 72 eyes, respectively). Overall, at m12 and m24, 91 eyes (94.8%) and 84 eyes (87.5%) lost fewer than 15 letters, and 25 (26%) eyes and 24 eyes (25%) improved by 15 letters or more, respectively; five eyes (5.2%) and 12 eyes (12.5%) lost more than 15 letters, at m12 and m24, respectively.
  
  
  CONCLUSIONS
  In this study, similarly to other studies of variable dosing regimen over 24 months, intravitreal ranibizumab was effective in significantly increasing BCVA and reducing CMT.
authors: Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, Creteil, France. giuseppe.querques@hotmail.it
authors: Giuseppe
authors: G
authors: Querques
authors: Sophie
authors: S
authors: Azrya
authors: Domenico
authors: D
authors: Martinelli
authors: Elya
authors: E
authors: Berboucha
authors: Audrey
authors: A
authors: Feldman
authors: Alfredo
authors: A
authors: Pece
authors: Gabriel
authors: G
authors: Coscas
authors: Gisèle
authors: G
authors: Soubrane
authors: Eric H
authors: EH
authors: Souied
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab